Johnson & Johnson has opened the doors of its new biotech incubator, bringing in its first 10 resident startups and hoping to galvanize the next generation of life sciences innovators.
After months of speculation, Johnson & Johnson, the world's biggest maker of healthcare products, put the rumors to rest by confirming the sale of its Cordis vascular device unit to Cardinal Health for $1.9 billion. The deal is expected to be completed by the end of the year.
Johnson & Johnson has launched a health and wellness platform that's slated to function across all its businesses. The pan-corporate initiative launched with an example from its orthopedics player DePuy Synthes--the Patient Athlete program to help joint replacement patients better manage pain reduction before and after surgery.
Continuous glucose monitor company DexCom turned a profit for the first time during the fourth quarter of last year. It also said it completed its FDA submission for its first direct-access smartphone CGM, the G5, which transmits data directly to a smartphone and from the phone to a secure system.
It's bad news and good news for Johnson & Johnson's legal department today. South Carolina's Supreme Court upheld a jury verdict against the company in a Risperdal marketing lawsuit, but did slash the $327 million judgment by more than half.
The FDA wants some more time to review Hospira and partner Celltrion's copy of Johnson & Johnson's blockbuster autoimmune drug Remicade, possibly delaying the drug's march onto the U.S. market.
So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going.
The jury has spoken in Johnson & Johnson's Risperdal trial, and the news wasn't good for the U.S.-based drugmaker. The Philadelphia panel decided J&J had failed to properly warn that the antipsychotic drug could trigger breast development in boys and young men, in the first of more than 1,000 similar cases pending.
Partners Hospira and Celltrion are marching forward with copies of Johnson & Johnson's blockbuster autoimmune drug Remicade, bulldozing into Europe with products expected to disrupt a multibillion-dollar market.
Johnson & Johnson is shelling out as much as $420 million to resolve claims over recalled hip implants, adding to its previous $2.5 billion settlement and laying more lawsuits in its ongoing courtroom battle to rest.